Pemphigus Foliaceus and Pemphigus Erythematosus

  • Christoph M. Hammers
  • Enno SchmidtEmail author
  • Luca Borradori


Pemphigus foliaceus (PF) is a chronic autoimmune blistering disease of the skin, characterized by autoantibodies against a structural component of the epidermal desmosome, desmoglein 1 (Dsg1). Pemphigus erythematosus (PE; syn. Senear-Usher syndrome) is a localized form of PF with lesions typically developing on the face and the upper trunk and back. Management of pemphigus foliaceus does not greatly differ from that of pemphigus vulgaris. Systemic corticosteroids represent the mainstay of therapy and are usually combined with an immunosuppressive adjuvant.


Desmoglein 1 Fogo selvagem Review Senear-Usher syndrome Treatment 





American College of Rheumatology














Intravenous immunoglobulins


Mycophenolate mofetil


Mycophenolic acid




Pemphigus erythematosus


Pemphigus foliaceus


Randomized controlled clinical trials




Thiopurine methyltransferase


  1. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772–9.CrossRefGoogle Scholar
  2. Behzad M, Mobs C, Kneisel A, et al. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol. 2012;166:844–52.CrossRefGoogle Scholar
  3. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006;142:1447–54.CrossRefGoogle Scholar
  4. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57:622–8.CrossRefGoogle Scholar
  5. Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 guideline for diagnosis and treatment; accessible online at 2013.
  6. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545–52.CrossRefGoogle Scholar
  7. Kasperkiewicz M, Eming R, Behzad M, et al. Efficacy and safety of rituximab in pemphigus: experience of the German registry of autoimmune diseases. J Dtsch Dermatol Ges. 2012a;10:727–32.PubMedGoogle Scholar
  8. Kasperkiewicz M, Shimanovich I, Meier M, et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol. 2012b;166:154–60.CrossRefGoogle Scholar
  9. Leshem YA, Hodak E, David M, et al. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol. 2013;68:404–11.CrossRefGoogle Scholar
  10. Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148:1031–6.CrossRefGoogle Scholar
  11. Ratnam KV, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens. A 5-year study. Int J Dermatol. 1990;29:363–7.CrossRefGoogle Scholar
  12. Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci. 2009;1173:683–91.CrossRefGoogle Scholar
  13. Sethy PK, Khandpur S, Sharma VK. Randomized open comparative trial of dexamethasone-cyclophosphamide pulse and daily oral cyclophosphamide versus cyclophosphamide pulse and daily oral prednisolone in pemphigus vulgaris. Indian J Dermatol Venereol Leprol. 2009;75:476–82.CrossRefGoogle Scholar
  14. Werth VP, Fivenson D, Pandya AG, et al. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2008;144:25–32.CrossRefGoogle Scholar

Further Reading

  1. Amagai M, Stanley JR. Desmoglein as a target in skin disease and beyond. J Invest Dermatol. 2012;132:776–84.CrossRefGoogle Scholar
  2. Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60:595–603.CrossRefGoogle Scholar
  3. Aoki V, Sousa Jr JX, Diaz LA, Cooperative Group on Fogo Selvagem Research. Pathogenesis of endemic pemphigus foliaceus. Dermatol Clin. 2011;29:413–8, viii.CrossRefGoogle Scholar
  4. Bastuji-Garin S, Souissi R, Blum L, et al. Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women. J Invest Dermatol. 1995;104:302–5.CrossRefGoogle Scholar
  5. Beissert S, Mimouni D, Kanwar AJ, et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2010;130:2041–8.CrossRefGoogle Scholar
  6. Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol. 1998;16:393–7.CrossRefGoogle Scholar
  7. Empinotti JC, Aoki V, Filgueira A, et al. Clinical and serological follow-up studies of endemic pemphigus foliaceus (fogo selvagem) in Western Parana, Brazil (2001–2002). Br J Dermatol. 2006;155:446–50.CrossRefGoogle Scholar
  8. Gurcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol. 2009;161:723–31.CrossRefGoogle Scholar
  9. Hammers CM, Lunardon L, Schmidt E, Zillikens D. Contemporary management of pemphigus. Expert Opin Orphan Drugs. 2013;1:295–314.CrossRefGoogle Scholar
  10. Ishii K, Lin C, Siegel DL, Stanley JR. Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies. J Invest Dermatol. 2008;128:939–48.CrossRefGoogle Scholar
  11. James KA, Culton DA, Diaz LA. Diagnosis and clinical features of pemphigus foliaceus. Dermatol Clin. 2011;29:405–12, viii.CrossRefGoogle Scholar
  12. Martin LK, Werth V, Villanueva E, et al. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009. doi: 10.1002/14651858. CD006263.pub2:CD006263.
  13. Mentink LF, Mackenzie MW, Toth GG, et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol. 2006;142:570–6.CrossRefGoogle Scholar
  14. Meyersburg D, Schmidt E, Kasperkiewicz M, Zillikens D. Immunoadsorption in dermatology. Ther Apher Dial. 2012;16:311–20.CrossRefGoogle Scholar
  15. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58:1043–6.CrossRefGoogle Scholar
  16. Oktarina DA, Poot AM, Kramer D, et al. The IgG “lupus-band” deposition pattern of pemphigus erythematosus: association with the desmoglein 1 ectodomain as revealed by 3 cases. Arch Dermatol. 2012;148:1173–8.CrossRefGoogle Scholar
  17. Qian Y, Jeong JS, Maldonado M, et al. Cutting Edge: Brazilian pemphigus foliaceus anti-desmoglein 1 autoantibodies cross-react with sand fly salivary LJM11 antigen. J Immunol. 2012;189:1535–9.CrossRefGoogle Scholar
  18. Schmidt E, Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev. 2010;10:84–9.CrossRefGoogle Scholar
  19. Schmidt E, Zillikens D. Immunoadsorption in dermatology. Arch Dermatol Res. 2010;302:241–53.CrossRefGoogle Scholar
  20. Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med. 2006;355:1800–10.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Christoph M. Hammers
    • 1
    • 2
  • Enno Schmidt
    • 2
    Email author
  • Luca Borradori
    • 3
  1. 1.Department of DermatologyUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of DermatologyUniversity of LübeckLübeckGermany
  3. 3.Department of DermatologyBern University HospitalBernSwitzerland

Personalised recommendations